hereby revoke all previous powers of atto 7 CFR 3.73(b).	mey given in the application	on identified in the atta	ched statement under
hereby appoint:			
Practitioners associated with the Customer Nu	mber: 45511	1	
OR			
Practitioner(s) named below (if more than ten	patent practitioners are to be nam	ed, then a customar number	er must be used);
Name	Registration Number	. Name	Registration Number
	<b>S</b>		
s attorney(s) or agent(s) to represent the undersign ny and all patent applications assigned only to the undersided to this form in accordance with 37 CFR 3.7.	undersigned according to the USF 3(b).	TO essignment records or	assignment documents
Please change the correspondence address for the	application identified in the attach	ed statement under 37 CFR	3.73(b) to:
Tital.			
The address associated with Customer Nu	mber: 45511		
OR Firm or			
Individual Name			
Address			
	State		Zip
Address City	State		Zip
Address  City  Country			Zip
Address City	State		Zip
Address  City  Country  Telephone			Zip
Address City Country Telephone Assignes Neme and Address:	Em		Zip 
Address  City  Country  Telephone	Em		Zip
Address City Country Telephone Assigned Nerms and Address: Jamssen Pharmaceutics N.V.	Em		22p
Adduse Cily Country Yelsphone Assignee Nemm and Address: Jamssen Pharmaceutica N.V. Turnhoutseweg 30 Beerse, Belgium B-2340	Em		965
Address City Country Telephone Assignee Nerms and Address: Janassen Pharmaceutics N.V. Turnhoutseveg 30 Beersc, Belgium B-2340 A copy of this form, together with a statem	ent under 37 CFR 3,73(b) (Fr is used. The statement und	orm PTO/SB/95 or equi	met, valent) is required to b
Address  City Courtey Telephone  Assignes Neme and Address: Jamssen Pharmaceutics N.V. Turnhoutseweg 30 Beersc, Belgium B-2340  A copy of this form, together with a statem tiled in each application in which this form the practitioners appointed in this form if if	ent under 37 CFR 3,73(b) (F- is used. The statement under	orm PTO/SB/95 or equi ler 37 CFR 3.750 for on	met, valent) is required to b
Address City Telephone Assignee Nerms and Address: Jatussen Pharmaceutica N.V. Turnhouteséeg 30 Beerse, Belgium B-2340 A copy of this form, together with a statem filed in each application in which this form the practitioners appointed in this form if if	ent under 37 CFR 3.73(b) (F- is used. The statement und ne appointed practitioner is this Power of Atomay is to	orm PTO/SS/95 or equi ler 37 CFR 3.75(b) may authorized topact on bi be filed. I	met, valent) is required to b
Address City Telephone Assignee Nerms and Address: Jatussen Pharmaceutica N.V. Turnhouteséeg 30 Beerse, Belgium B-2340 A copy of this form, together with a statem filed in each application in which this form the practitioners appointed in this form if if	ent under 37 CFR 3.73(b) (Fi in used. The statement und the appointed practitioner is this Power of Attorney is to	orm PTO/SE/S\$ or equivalent of the state of	valent) is required to be completed by one chalf of the assignee.
City Courtsy Telephone Lesignee Nerme and Address: Jamssen Pharmaceutica N.V. Turnhoutseweg 30 Beerse, Belgrium B-2340 A copy of this form, together with a statem filed in sech application in which this form the practitioners appointed in this form if the and must identify the application in which The Ladvidual whose signature is	ent under 37 CFR 3.73(b) (Fi in used. The statement und the appointed practitioner is this Power of Attorney is to	orm PTO/SE/S\$ or equivalent of the state of	valent) is required to be completed by one chalf of the assignee.
City Courtey Totephone  Assignee Neme and Address: Jamesen Pharmaceutica N.V. Turnhoutseweg 30 Beerse, Belgium B-2340  A copy of title form, together with a statem filled in each application in which this form the practitioners appointed in this form if if and must identify the application in which:	ent under 37 CFR 3.73(b) (Fi in used. The statement und the appointed practitioner is this Power of Attorney is to	porm PTO/SB/95 or equivalent 37 CFR 3.72 (b) may authorized typact on be brilled.	valent) is required to be completed by one chalf of the assignee,

comments on the princing of the ground of the comments of the

STATEMENT UNDER 37 CFR	3.73(b)
Applicant/Patent Owner: JANSSEN PHARMACEUTICA N.V.	
Application No./Patent No.: 10/552,527 Filed/Issue Date: 10/1	1/2005
Entitled: SUBSTITUTED 4-PHENYL4-[1H-IMIDAZOL-2-YL]-PIPERIDINE DERIVAT OPIOD AGONISTS WITH ANTIDEPRESSANT AND ANXIOLYTIC ACTIVIT	
JANSSEN PHARMACEUTICA N.V. , a CORPORATION (Type of Assignee, e.g., c	orporation, partnership, university, government agency, etc.)
states that it is:  1.   the assignee of the entire right, title, and interest; or	
an assignee of less than the entire right, title and interest (The extent (by percentage) of its ownership interest is	
n the patent application/patent identified above by virtue of either:	
A. An assignment from the inventor(s) of the patent application/patent ider in the United States Patent and Trademark Office at Reel thereof is attached.	
OR B. / A chain of title from the inventor(s), of the patent application/patent iden	tified above, to the current assignee as follows:
1. From: INVENTORS *1, *2, *3 AND *4 To: JANSSEN PH	HARMAGELITICA N.V.
The document was recorded in the United States Patent and Tra	ademark Office at
Reel 019191 , Frame 0136 , or for which	a copy thereof is attached.
2. From: _INVENTORS "5 AND "6 To: _JANSSEN-CI	LAG S.A.
The document was recorded in the United States Patent and Tra	
Reel <u>019191</u> , Frame <u>0147</u> , or for whic	n a copy thereof is attached.
3. From: JANSSEN-CILAG S.A. To: JANSSEN PH	IARMACEUTICA N.V.
The document was recorded in the United States Patent and Tra	ademark Office at
Reel <u>019191</u> , Frame <u>0144</u> , or for whi	ch a copy thereof is attached.
Additional documents in the chain of title are listed on a supplement	al sheet.
As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the classignee was, or concurrently is being, submitted for recordation pursuant to	
[NOTE: A separate copy (i.e., a true copy of the original assignment docu Division in accordance with 37 CFR Part 3, to record the assignmen 302.08]	
The undersigned (whose title is supplied below) is authorized to act on behalf	of the assignee.
/S. Maurice Valla/	April 25, 2007
Signature	Date
S. MAURICE VALLA	215-568-3100
Printed or Typed Name	Telephone Number
ATTORNEY FOR APPLICANT/REG. NO. 43 966	

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 monutes to concern the control of the confidential process. The confidential process are control of the confidential process. The confidential process are confidentially an advantage of the confidential process. The confidential process are confidentially as a confidential process. The confidential process are confidentially as a confidential process. The confidential process are confidentially as a confidential process. The confidential process are confidentially as a confidential process. The confidential process are confidentially as a confidential process. The confidential process are confidentially as a confidential process. The confidential process are confidentially as a confidential process. The confidential process are confidentially as a confidential process. The confidential process are confidentially as a confidential process. The confidential process are confidentially as a confidential process. The confidential process are confidentially as a confidential process. The confidential process are confidentially as a confidential process. The confidential process are confidentially as a confidential process. The confidential process are confidentially as a confidential process. The confidential process are confidentially as a confidential process. The confidential process are confidentially as a confidential process. The confidential process are confidentially as a confidential process are confidentially as a confidential process. The confidential process are confidentially as a confidential process are confidentially as a confidential process. The confidential process are confidentially as a confidential process. The confidential process are confidentially as a confidential process are confidentially as a confidential process.